A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
Clinical trial NCT03205046 · TERMINATED
Trial details
- NCT number
- NCT03205046
- Sponsor
- Acerta Pharma BV
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-06-29
- Primary completion
- 2019-11-20
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.